Sonova gains fresh analyst support, Morgan Stanley and JPMorgan lift views on the shares

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 14:09.

Sonova Holding AG (CH0012549785) is drawing renewed analyst interest this week after two major houses raised their stance on the Zurich-listed hearing care group. Morgan Stanley and JPMorgan both now see more upside in the shares, according to recent analyst updates.

Morgan Stanley lifts rating and target

Morgan Stanley has upgraded Sonova from "Underweight" to "Equalweight" and lifted its price target from 172 CHF to 205 CHF, citing a growing global hearing-aid market and solid fundamentals at the Swiss group. Investing.com reports on the Morgan Stanley update The bank highlights Sonova's approximately 14.2 billion USD market capitalization and a price-earnings ratio around 21.5 as indicators of a mature but still growing franchise. The same analysis outlines valuation metrics and sector backdrop

The rating change comes at a time when established hearing-care peers like Demant and GN Store Nord are also benefiting from demographic trends in the US and Europe, where aging populations support steady demand for audiological solutions. A Reuters report on hearing-aid makers underlines the favorable demand backdrop With Sonova traded on SIX Swiss Exchange in Zurich, the stock remains a key healthcare component for investors tracking Swiss indices such as the SMI and SPI.

JPMorgan also turns more positive

JPMorgan has moved its rating on Sonova from "Neutral" to "Overweight", while nudging its price target higher from 158 CHF to 163 CHF according to the same analyst round-up. Investing.com notes the JPMorgan upgrade alongside Morgan Stanley's move The US bank points to improving momentum in Sonova's core devices business and continuing integration benefits in its audiological care network.

Consensus data from MarketScreener show that a majority of analysts now rate Sonova at least "Hold", with a significant share on "Buy" or equivalent ratings, and an average 12-month price target in the low 200 CHF range. MarketScreener's Sonova consensus page summarizes current ratings and targets For investors in Europe and beyond who track healthcare exposure via benchmarks like the Stoxx Europe 600, Sonova's analyst recalibration delivers an updated reference point.

The business behind Sonova

Sonova generates most of its revenue with hearing instruments and cochlear implants, marketed under brands such as Phonak, Unitron and Advanced Bionics across Europe, North America and Asia-Pacific. The latest Sonova annual report details revenue split by segment and region The group also operates a global audiological care network of specialist retailers that fit and service hearing devices.

Where the Sonova shares trade today

The Sonova shares (CH0012549785) trade on SIX Swiss Exchange in Zurich; as of 2026-06-23, 11:55 local time they change hands at 275.00 CHF according to the Swiss exchange data.

This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Investors should conduct their own research or consult a qualified financial advisor before making investment decisions.